Hypoxia signalling in tumour angiogenesis

Expert Opinion on Therapeutic Targets

Volumn 4, Issue 3, 2000, Pages 361-375

  Knies, Ulrike E ^a   Harris, Adrian L ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

angiogenesis inhibitors; hypoxia; hypoxia inducible factor 1 (HIF 1); tumour angiogenesis; vascular endothelial growth factor (VEGF)

Indexed keywords

EID: 0010500472     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.4.3.361     Document Type: Review

References (113)

1. BENJAMIN LE, GOLIJANIN D, ITIN A, PODE D, KESHET E: Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. (1999) 103:159-165. (Pubitemid 29053133)
2. PEZZELLA F, PASTORINO U, TAGLIABUE E et al.: Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. (1997) 151:1417-1423. (Pubitemid 27479772)
3. HOLASH J, MAISONPIERRE PC, COMPTON D et al.: Vessel cooption, regression and growth in tumors mediated by angiopoietins and VEGF. Science (1999) 284:1994-1998. (Pubitemid 29309448)
4. HANAHAN D, FOLKMAN J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 86:353-364. (Pubitemid 26272076)
5. RISAU W: What, if anything, is an angiogenic factor? Cancer Metastasis Rev. (1996) 15:149-151. (Pubitemid 26236111)
6. ROCKWELL S: Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol. Res. (1997) 9:383-390. (Pubitemid 127825992)
7. VAUPEL P, SCHLENGER K, KNOOP C,HOCKEL M: Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. (1991) 51:3316-3322.
8. HOCKEL M, SCHLENGER K, KNOOP C, VAUPEL P: Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 tension measurements. Cancer Res. (1991) 51:6098-6102.
9. DUNN T: Oxygen and cancer. N. C. Med. J. (1997) 58:140-143.
10. FOX SB: Tumour angiogenesis and prognosis. Histopathology (1997) 30:294-301. (Pubitemid 27148164)
11. LEEK RD, LANDERS RJ, HARRIS AL, LEWIS CE: Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast. Br. J. Cancer (1999) 79:991-995. (Pubitemid 29082138)
12. FOLKMAN J: Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. (1972) 175:409-416.
13. SCHNITZER JE: Vascular targeting as a strategy for cancer therapy. N. Engl. J. Med. (1998) 339:472-474. (Pubitemid 28377692)
14. RAN S, GAO B, DUFFY S et al.: Infarction of solid Hodgkin's tumors in mice by antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res. (1998) 58:4646-4653. (Pubitemid 28480630)
15. ZHU Z, WITTE L: Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest. New Drugs (1999) 17:195-212. (Pubitemid 30037954)
16. O'REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell (1994) 79:315-328 . (Pubitemid 24324921)
17. O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88:277-285. (Pubitemid 28015876)
18. MARTI HH,RISAU W: Angiogenesis in ischemic disease [in process citation]. Thromb. Haemost. (1999) 82(Suppl. 1):44-52. (Pubitemid 30093630)
19. FERRARA N: Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. (1999) 56:794-814. (Pubitemid 29411709)
20. GLEADLE JM, EBERT BL, FIRTH JD, RATCLIFFE PJ: Regulation of angiogenic growth factor expression by hypoxia, transition metals and chelating agents. Am. J. Physiol. (1995) 268:C1362-C1368.
21. IKEDA E, ACHEN MG, BREIER G, RISAU W: Hypoxiainduced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. (1995) 270:19761-19766.
22. FORSYTHE JA, JIANG BH, IYER NV et al.: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. (1996) 16:4604-4613. (Pubitemid 26272112)
23. CLAUSS M, GRELL M, FANGMANN C et al.: Synergistic induction of endothelial tissue factor by tumor necrosis factor and vascular endothelial growth factor: functional analysis of the tumor necrosis factor receptors. FEBS Lett. (1996) 390:334-338. (Pubitemid 26248971)
24. FERRARA N, DAVIS-SMYTH T: The biology of vascular endothelial growth factor. Endocr. Rev. (1997) 18:4-25. (Pubitemid 27076453)
25. ESSER S, WOLBURG K, WOLBURG H et al.: Vascular endothelial growth factor induces endothelial fenestrations in vitro. J. Cell Biol. (1998) 140:947-959. (Pubitemid 28141231)
26. MEESON AP, ARGILLA M, KO K, WITTE L, LANG RA: VEGF deprivation-induced apoptosis is a component of programmed capillary regression. Development (1999) 126:1407-1415. (Pubitemid 29195230)
27. GERBER HP, DIXIT V, FERRARA N: Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. (1998) 273:13313-13316. (Pubitemid 28246905)
28. FERRARA N, CARVER-MOORE K, CHEN H et al.: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature (1996) 380:439-442. (Pubitemid 26102720)
29. CARMELIET P, FERREIRA V, BREIER G et al.: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 380:435-439. (Pubitemid 26102719)
30. FONG GH, ROSSANT J, GERTSENSTEIN M, BREITMAN ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature (1995) 376:66-70.
31. SHALABY F, ROSSANT J, YAMAGUCHI TP et al.: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature (1995) 376:62-66.
32. SOKER S, TAKASHIMA S, MIAO HQ, NEUFELD G, KLAGSBRUN M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell (1998) 92:735-745. (Pubitemid 28155313)
33. CAO Y, CHEN H, ZHOU L et al.: Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression and high affinity binding to Flk-1/KDR. J. Biol. Chem. (1996) 271:3154-3162. (Pubitemid 26060529)
34. TAKAHASHI T, UENO H, SHIBUYA M: VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene (1999) 18:2221-2230. (Pubitemid 29186923)
35. FUKUMURA D, XAVIER R, SUGIURA T et al.: Tumor induction of VEGF promoter activity in stromal cells. Cell (1998) 94:715-725. (Pubitemid 28436004)
36. SHIBUYA M: Role of VEGF-flt receptor system in normal and tumor angiogenesis. Adv. Cancer Res. (1995) 67:281-316.
37. MILLAUER B, LONGHI MP, PLATE KH et al.: Dominantnegative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res. (1996) 56:1615-1620. (Pubitemid 26104026)
38. TAKAHASHI Y, KITADAI Y, BUCANA CD, CLEARY KR, ELLIS LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Cancer Res. (1995) 55:3964-3968.
39. KIM KJ, LI B, WINER J et al.: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 362:841-844. (Pubitemid 23132159)
40. SKOBE M, ROCKWELL P, GOLDSTEIN N, VOSSELER S, FUSENIG NE: Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. (1997) 3:1222-1227. (Pubitemid 27508822)
41. WARREN RS, YUAN H, MATLI MR, GILLETT NA, FERRARA N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. (1995) 95:1789-1797.
42. MELNYK O, SHUMAN MA, KIM KJ: Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth. Cancer Res. (1996) 56:921-924. (Pubitemid 26055486)
43. WITTE L, HICKLIN DJ, ZHU Z et al.: Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. (1998) 17:155-161. (Pubitemid 28391949)
44. FONG TA, SHAWVER LK, SUN L et al.: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res. (1999) 59:99-106. (Pubitemid 29062964)
45. WANG GL, JIANG BH, RUE EA et al.: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA (1995) 92: 5510-5514.
46. HOGENESCH JB, GU YZ, JAIN S, BRADFIELD CA: The basic-helix-loop-helix-PAS orphan MOP3 forms transcriptionally active complexes with circadian and hypoxia factors. Proc. Natl. Acad. Sci. USA (1998) 95:5474-5479. (Pubitemid 28224118)
47. KOBAYASHI A, NUMAYAMA-TSURUTA K, SOGAWA K, FUJII-KURIYAMA Y: CBP/p300 functions as a possible transcriptional coactivator of Ah receptor nuclear translocator (ARNT). J. Biochem. (Tokyo) (1997) 122:703-710. (Pubitemid 27474937)
48. TAKAHATA S, SOGAWA K, KOBAYASHI A et al.: Transcriptionally active heterodimer formation of an ARNT-like PAS protein, ARNT3, with HIF-1?, HLF and clock. Biochem. Biophys. Res. Commun. (1998) 248:789-794. (Pubitemid 28404501)
49. MOFFETT P, REECE M, PELLETIER J: The murine Sim-2 gene product inhibits transcription by active repression and functional interference. Mol. Cell Biol. (1997) 17:4933-4947. (Pubitemid 27357593)
50. WENGER RH, GASSMANN M: Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. (1997) 378:609-616. (Pubitemid 27361853)
51. WENGER RH, ROLFS A, MARTI HH, GUENET JL, GASSMANN M: Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxiainducible factor-1 alpha. Biochem. Biophys. Res. Commun. (1996) 223:54-59. (Pubitemid 26202477)
52. WIENER CM, BOOTH G, SEMENZA GL: In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. (1996) 225:485-488. (Pubitemid 26355627)
53. SALCEDA S, CARO J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. (1997) 272:22642-22647. (Pubitemid 27386079)
54. RICHARD DE, BERRA E, GOTHIE E, ROUX D, POUYSSEGUR J: p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. (1999) 274:32631-32637. (Pubitemid 129535289)
55. IYER NV, KOTCH LE, AGANI F et al.: Cellular and developmental control of O2 homeostasis by hypoxiainducible factor 1 alpha. Genes Dev. (1998) 12:149-162. (Pubitemid 28060446)
56. CARMELIET P, DOR Y, HERBERT JM et al.: Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis [published erratum appears in Nature (1998) 395(6701):525]. Nature (1998) 394:485-490.
57. RYAN HE, LO J, JOHNSON RS: HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. (1998) 17:3005-3015. (Pubitemid 28254373)
58. KALLIO PJ, PONGRATZ I, GRADIN K, MCGUIRE J, POELLINGER L: Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc. Natl. Acad. Sci. USA (1997) 94:5667-5672. (Pubitemid 27241827)
59. SEMENZA GL, WANG GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. (1992) 12:5447-5454.
60. PINSKY DJ, LIAO H, LAWSON CA et al.: Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J. Clin. Invest. (1998) 102:919-928. (Pubitemid 28419237)
61. GRAHAM CH, FITZPATRICK TE, MCCRAE KR: Hypoxia stimulates urokinase receptor expression through a heme protein-dependent pathway. Blood (1998) 91:3300-3307. (Pubitemid 28193880)
62. MAXWELL PH, WIESENER MS, CHANG GW et al.: The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature (1999) 399:271-275. (Pubitemid 29246458)
63. TIAN H, MCKNIGHT SL, RUSSELL DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. (1997) 11:72-82. (Pubitemid 27043825)
64. FLAMME I, FROHLICH T, VON REUTERN M et al.: HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech. Dev. (1997) 63:51-60. (Pubitemid 27214502)
65. EMA M, TAYA S, YOKOTANI N et al.: A novel bHLH-PAS factor with close sequence similarity to hypoxiainducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA (1997) 94:4273-4278.
66. HOGENESCH JB, CHAN WK, JACKIW VH et al.: Characterization of a subset of the basic-helix-loop-helix-PAS superfamily that interacts with components of the dioxin signaling pathway. J. Biol. Chem. (1997) 272:8581-8593. (Pubitemid 27147824)
67. CONRAD PW, FREEMAN TL, BEITNER-JOHNSON D, MILLHORN DE: EPAS1 trans-activation during hypoxia requires p42/p44 MAPK. J. Biol. Chem. (1999) 274:33709-33713. (Pubitemid 129511686)
68. GRAEBER TG, OSMANIAN C, JACKS T et al.: Hypoxiamediated selection of cells with diminished apoptotic potential in solid tumours [see comments]. Nature (1996) 379:88-91. (Pubitemid 26008141)
69. BUNZ F, HWANG PM, TORRANCE C et al.: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. (1999) 104:263-269.
70. BLANDINO G, LEVINE AJ, OREN M: Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 18:477-485, (Pubitemid 29060623)
71. DAMERON KM, VOLPERT OV, TAINSKY MA, BOUCK N: Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (1994) 265:1582-1584. (Pubitemid 24308973)
72. MUKHOPADHYAY D, TSIOKAS L, SUKHATME VP: Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. (1995) 55:6161-6165.
73. RAVI R, MOOKERJEE B, BHUJWALLA ZM et al.: Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. (2000) 14:34-44. (Pubitemid 30051577)
74. MATSUI H, IHARA Y, FUJIO Y et al.: Induction of interleukin (IL)-6 by hypoxia is mediated by nuclear factor (NF)-kappa B and NF-IL6 in cardiac myocytes. Cardiovasc. Res. (1999) 42:104-112. (Pubitemid 29167075)
75. YAN SF, LU J, ZOU YS et al.: Hypoxia-associated induction of early growth response-1 gene expression. J. Biol. Chem. (1999) 274:15030-15040.
76. YAN SF, ZOU YS, GAO Y et al.: Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc. Natl. Acad. Sci. USA (1998) 95:8298-8303. (Pubitemid 28326107)
77. BAE SK, BAE MH, AHN MY et al.: Egr-1 mediates transcriptional activation of IGF-II gene in response to hypoxia. Cancer Res. (1999) 59:5989-5994.
78. GRUGEL S, FINKENZELLER G, WEINDEL K, BARLEON B, MARME D: Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. (1995) 270:25915-25919.
79. MAZURE NM, CHEN EY, LADEROUTE KR, GIACCIA AJ: Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-rastransformed cells through a hypoxia inducible factor-1 transcriptional element. Blood (1997) 90:3322-3331. (Pubitemid 27473400)
80. JIANG BH, AGANI F, PASSANITI A, SEMENZA GL: V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. (1997) 57:5328-5335. (Pubitemid 27516371)
81. PETIT AM, RAK J, HUNG MC et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. (1997) 151:1523-1530. (Pubitemid 27527914)
82. PELENGARIS S, LITTLEWOOD T, KHAN M, ELIA G, EVAN G: Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol. Cell (1999) 3:565-577. (Pubitemid 29268440)
83. BARR LF, CAMPBELL SE, DIETTE GB et al.: c-Myc suppresses the tumorigenicity of lung cancer cells and down regulates vascular endothelial growth factor expression. Cancer Res. (2000) 60:143-149. (Pubitemid 30058744)
84. BUSH RS, JENKIN RD, ALLT WE et al.: Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer Suppl. (1978) 37:302-306.
85. GRAU C, OVERGAARD J: Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol. (1988) 13:301-309. (Pubitemid 19009245)
86. GRAY LH, CONGER AD, EBERT M, HORNSEY S, SCOTT OC: Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J. Radiol. (1953) 26:638-648.
87. PALLAVICINI MG, LALANDE ME, MILLER RG, HILL RP: Cell cycle distribution of chronically hypoxic cells and determination of the clonogenic potential of cells accumulated in G2 + M phases after irradiation of a solid tumor in vivo. Cancer Res. (1979) 39:1891-1897. (Pubitemid 9184974)
88. AMELLEM O, PETTERSEN EO: Cell inactivation and cell cycle inhibition as induced by extreme hypoxia: the possible role of cell cycle arrest as a protection against hypoxia-induced lethal damage. Cell Prolif. (1991) 24:127-141.
89. KERR DJ, KAYE SB: Aspects of cytotoxic drug penetration, with particular reference to anthracyclines. Cancer Chemother. Pharmacol. (1987) 19:1-5. (Pubitemid 17017029)
90. FISCHER JJ, ROCKWELL S, MARTIN DF: Perfluorochemicals and hyperbaric oxygen in radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (1986) 12:95-102. (Pubitemid 16180223)
91. STONE HB, WITHERS HR: Enhancement of the radioresponse of a murine tumour by a nitroimidazole. Br. J. Radiol. (1975) 48:411-412.
92. DISCHE S, SAUNDERS MI, LEE ME, ADAMS GE, FLOCKHART IR: Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses. Br. J. Cancer (1977) 35:567-579. (Pubitemid 8107820)
93. BROWN JM: SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer (1993) 67:1163-1170. (Pubitemid 23172847)
94. BROWN JM: Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine. Br. J. Cancer (1998) 4:12-14.
95. ROWINSKY EK: Novel radiation sensitizers targeting tissue hypoxia. Oncology (Huntington) (1999) 13:61-70.
96. LEE DJ, TROTTI A, SPENCER S et al.: Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study. Int. J. Radiat. Oncol. Biol. Phys. (1998) 42:811-815. (Pubitemid 28559423)
97. KOVACS MS, HOCKING DJ, EVANS JW et al.: Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br. J. Cancer (1999) 80:1245-1251. (Pubitemid 29264086)
98. MILLER VA, NG KK, GRANT SC et al.: Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. (1997) 8:1269-1271. (Pubitemid 28164084)
99. DORIE MJ, BROWN JM: Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother. Pharmacol. (1997) 39:361-366. (Pubitemid 27047482)
100. WANG CY, GUTTRIDGE DC, MAYO MW, BALDWIN AS, Jr.: NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapyinduced apoptosis. Mol. Cell Biol. (1999) 19:5923-5929. (Pubitemid 29399297)
101. WANG CY, CUSACK JC, JR., LIU R, BALDWIN AS, JR.: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Med. (1999) 5:412-417. (Pubitemid 29180579)
102. DACHS GU, PATTERSON AV, FIRTH JD et al.: Targeting gene expression to hypoxic tumor cells. Nature Med. (1997) 3:515-520. (Pubitemid 27198648)
103. LEUNG DW, CACHIANES G, KUANG WJ, GOEDDEL DV, FERRARA N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 246:1306-1309. (Pubitemid 20066716)
104. KECK PJ, HAUSER SD, KRIVI G et al.: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science (1989) 246:1309-1312. (Pubitemid 20066717)
105. OLOFSSON B, PAJUSOLA K, KAIPAINEN A et al.: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. USA (1996) 93:2576-2581. (Pubitemid 26104389)
106. GRIMMOND S, LAGERCRANTZ J, DRINKWATER C et al.: Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. (1996) 6:124-131. (Pubitemid 26111339)
107. JOUKOV V, PAJUSOLA K, KAIPAINEN A et al.: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. (1996) 15:1751-1757.
108. LEE J, GRAY A, YUAN J et al.: Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. USA (1996) 93:1988-1992. (Pubitemid 26079868)
109. ORLANDINI M, MARCONCINI L, FERRUZZI R, OLIVIERO S: Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family [published erratum appears in Proc. Natl. Acad. Sci. USA (1997) 94(4):1603]. Proc. Natl. Acad. Sci. USA (1996) 93:11675-11680.
110. YAMADA Y, NEZU J, SHIMANE M, HIRATA Y: Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics (1997) 42:483-488. (Pubitemid 27287391)
111. MEYER M, CLAUSS M, LEPPLE-WIENHUES A et al.: A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. (1999) 18:363-374. (Pubitemid 29041945)
112. LYTTLE DJ, FRASER KM, FLEMING SB, MERCER AA, ROBINSON AJ: Homologs of vascular endothelial growth factor are encoded by the poxvirus Orf virus. J. Virol. (1994) 68:84-92.
113. MAGLIONE D, GUERRIERO V, VIGLIETTO G, DELLI-BOVI P, PERSICO MG: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. USA (1991) 88:9267-9271. (Pubitemid 21915612)